[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,782,133
  • Shares Outstanding, K 105,440
  • Annual Sales, $ 7,700 K
  • Annual Income, $ -465,320 K
  • EBIT $ -545 M
  • EBITDA $ -556 M
  • 60-Month Beta 0.24
  • Price/Sales 489.80
  • Price/Cash Flow N/A
  • Price/Book 2.95

Options Overview Details

View History
  • Implied Volatility 60.09% (-2.69%)
  • Historical Volatility 62.01%
  • IV Percentile 39%
  • IV Rank 36.38%
  • IV High 95.22% on 12/17/25
  • IV Low 40.01% on 08/15/25
  • Expected Move (DTE 26) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.32
  • Today's Volume 95
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 2,737
  • Open Int (30-Day) 2,304
  • Expected Range 35.87 to 35.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.23
  • Number of Estimates 6
  • High Estimate $-1.04
  • Low Estimate $-1.35
  • Prior Year $-1.23
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.30 +11.05%
on 06/02/26
37.80 -5.11%
on 05/22/26
+1.17 (+3.37%)
since 05/18/26
3-Month
32.30 +11.05%
on 06/02/26
43.62 -17.77%
on 05/07/26
-0.18 (-0.50%)
since 03/18/26
52-Week
25.83 +38.87%
on 08/08/25
57.99 -38.14%
on 01/05/26
+5.37 (+17.61%)
since 06/18/25

Most Recent Stories

More News
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results...

CRNX : 35.87 (+0.34%)
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFYâ„¢ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable...

CRNX : 35.87 (+0.34%)
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee...

CRNX : 35.87 (+0.34%)
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals  Two oral presentations...

CRNX : 35.87 (+0.34%)
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference,...

CRNX : 35.87 (+0.34%)
Crinetics Pharmaceuticals Q1 Earnings Call Highlights

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported first-quarter 2026 results highlighting early commercial traction for its newly launched acromegaly treatment PALSONIFY and continued investment in a broad...

CRNX : 35.87 (+0.34%)
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

      PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter        Management Hosting Conference Call at...

CRNX : 35.87 (+0.34%)
Crinetics' First Commercial Quarter Tests Whether Acromegaly Launch Math Holds Beyond Trial Data

Barchart Research What to Expect from CRNX Earnings CRNX Generated May 6, 2026 Current Price $41.71 EPS Estimate $$-1.22 Consensus Rating Strong Buy Average Move 5.11% Crinetics' First Commercial Quarter...

CRNX : 35.87 (+0.34%)
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical...

CRNX : 35.87 (+0.34%)
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after...

CRNX : 35.87 (+0.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CRINETICS PHARMACEUTICALS is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. CRINETICS PHARMACEUTICALS is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 38.50
2nd Resistance Point 37.64
1st Resistance Point 36.76
Last Price 35.87
1st Support Level 35.02
2nd Support Level 34.16
3rd Support Level 33.28

See More

52-Week High 57.99
Fibonacci 61.8% 45.70
Fibonacci 50% 41.91
Fibonacci 38.2% 38.12
Last Price 35.87
52-Week Low 25.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.